B O A R D O F D I R E C T O R S

C A M E R O N P I R O N

Chairman and Director

Cameron Piron is an industry-recognized leader and innovator in

image-guided surgery. Prior to co-founding Synaptive Medical,

Cameron was president and co-founder of Sentinelle Medical, a

medical device company that developed and manufactured advanced

MRI-based breast imaging technologies. Sentinelle grew to over 200

employees and over $20 million in revenues before being acquired by

Hologic, Inc. in 2010. Cameron studied systems design engineering

at the University of Waterloo, followed by a graduate degree at the

University of Toronto in medical biophysics. His awards include the

Ontario Premier’s Catalyst Award for Best Young Innovator in 2008;

the University of Waterloo’s Alumni Achievement medal in 2009 for

leading Sentinelle Medical in researching and manufacturing leading-

edge MRI technologies that allow physicians to diagnose breast

cancer and other medical conditions faster and more accurately;

being named to Canada’s Top 40 Under 40™ list in 2009, which was

established by Caldwell Partners and celebrates the achievements of

young Canadians in the private, public and non-profit sectors; and

being the first Canadian ever to win R&D Magazine’s Innovator of

the Year award in 2008. In 2015, Cameron was named one of Fast

Company’s Most Creative People. He chairs Synaptive’s Board of

Directors and heads the company’s executive committee.

MKT-00612 Rev. A

R I C H A R D B U T L A N D

Director

Richard Butland is the managing partner of Kite Capital, a growth

orientated private investment firm. Prior to establishing Kite Capital,

Richard spent 15 years at Goldman Sachs. He joined Goldman

Sachs in 2000 in the UK Advisory Group and was named managing

director in 2006. He ran the UK M&A Advisory business in 2007

and subsequently moved to the Merchant Banking Division to head

its private equity activities in the UK and Energy across Europe.

Richard worked at IBJ Schroder Bank and PricewaterhouseCoopers

prior to Goldman Sachs. He earned a bachelor’s degree in finance

from Victoria University of Wellington and qualified as a chartered

accountant.

D AV I D C A L U O R I

Director

David Caluori joined General Atlantic as a principal in 2014 where

he focuses on investments in the healthcare sector. Prior to joining

General Atlantic, David was with Welsh, Carson, Anderson & Stowe,

where he focused exclusively on investments in the healthcare sector.

He began his career in healthcare investment banking at Piper Jaffray

and Jefferies. David is on the board of Oak Street Health and received

a bachelor of arts in economics from Brown University.

D AV I D G A L L O P

Director

David Gallop has 15 years of experience in medical software

development. He graduated with a B.A.Sc. in Electrical Engineering

from McGill University in 2000 and began his career at eFilm Medical,

remaining on board for two years following its acquisition by Merge

Healthcare. David then joined Sentinelle Medical and was one of the

primary architects of its Aegis Breast diagnostic software. Following

Sentinelle’s acquisition by Hologic, Inc., David co-founded Synaptive

Medical, and is now focused on the architecture and development of

Synaptive’s BrightMatter suite of software products.

MKT-00612 Rev. A

D O U G J A N Z E N

Director

Doug Janzen brings over 20 years of experience in life sciences

to Synaptive’s Board of Directors with leadership experience in

corporate finance, business development, and management. During

his nine-year tenure at Cardiome Pharma (NASDAQ: CRME), Doug held

a series of positions including chief financial officer (2003 to 2005),

president and chief business officer (2005 to 2009), and president

and CEO (2009 to 2012). During this time, he raised over C$300

million from investors, completed over C$1 billion in licensing deals,

and led a partnership with Merck to bring Cardiome’s lead product,

Brinavess, through to clinical approval and marketing in Europe.

Doug is currently co-founder and managing director of NorthView

Ventures, chairman and CEO of Aequus Pharmaceuticals, and serves

on the Boards of Aequus Pharmaceuticals, Alabaster Technologies,

Abcellera (chairman), Ico Therapeutics, Perimeter Medical Imaging, and

Renaissance Biosciences. Prior to Cardiome, Doug was an investment

banker with Cormark Securities, acting as managing director of life

sciences, and has completed over C$1 billion in equity financing for

Canadian biotech companies. Doug is past chair of LifeSciences BC,

has served as a director with Biotech Canada and is a past winner of

Business in Vancouver’s “Top 40 Under 40 Award.”

W E S H O D G E S

Director

Wes Hodges graduated from the University of Toronto’s Engineering

Science program in 2003. In 2001, he began his career in medical

imaging at eFilm Medical. Following its acquisition by Merge

Healthcare in 2002, Wes formed Sentinelle Medical’s software

division in 2005, developing its 3D Aegis Breast diagnostic and

interventional platform. A few years following Sentinelle’s acquisition

by Hologic, Inc. in 2010, Wes co founded Synaptive Medical where

he focuses on developing a unifying software framework across its

various products.

MKT-00612 Rev. A

A N D R E W P R O Z E S

Director

Andrew Prozes currently serves on the boards of Transunion, Cott

Corporation, Corporate Risk Holdings (CRH), Asset International,

Synaptive Medical, payfone, Scribestar and Ethoca. He chairs

the Human Resources & Compensation Committee for Cott, and

also chairs the Compensation Committees for Transunion, Ethoca

and CRH. Andrew has served on not-for-profit boards including

the CEELI Institute, the Bruce Museum in Greenwich, CT, and the

Executive Committee of The Atlantic Council in Washington, D.C.

From 2000 to 20111, Andrew was CEO of LexisNexis and served on

the board of directors of Reed Elsevier. His past industry association

experiences include serving as chairman of The US Information

Industry Association and on the boards of the Information Technology

Association of Canada and the Canadian Newspaper Association.

Andrew graduated from University of Waterloo with a bachelor of

mathematics in computer science, and received his MBA from York

University.

G A L A S E L A

Secretary and Director

Gal Sela brings 18 years of experience in medical imaging to

Synaptive. He has a background in electrical engineering and a

master’s degree in computer vision from McGill University. Gal began

his career in medical imaging as part of a Toronto Western Hopsital

(IGMIT) team involved in the intra-operative MRI system, where he

played a role from the early installation phases of the system and

supported neurosurgical procedures throughout its operational life.

Gal also developed the intra-operative, image-guided navigation

system that was used in conjunction with the IGMIT system. Other

research directions included detecting white matter disease, diffusion

fiber tractography, and lesion segmentation and classification. Prior

to co-founding Synaptive, Gal was co-founder and CTO of Sentinelle

Medical, where he oversaw the development of innovative imaging

technologies for breast and prostate cancer detection, including an

image-guided navigation system that integrated MRI with ultrasound

imaging and registration to soft tissue.

MKT-00612 Rev. A

P E T E R W E H R LY

Director

Until recently, Peter Wehrly was group president developed markets

at Covidien, the manufacturer of medical devices with sales of over

$10.7 billion (2014). Peter held profit and loss responsibility for the

marketing and sale of products to all developed markets outside

the U.S. between 2013 and 2015. The division had sales of over

$3.9 billion, and accounted for 34 percent of global revenue and 62

percent of global operating income. He departed following the $42

billion sale of Covidien to Medtronic in 2015. Prior to this role, Peter

was the president of Respiratory and Monitoring Solutions. He led

the division’s turnaround from a negative revenue growth rate of -4.3

percent in 2009 to +3.5 percent in 2010. He was also responsible for

Covidien’s Japanese, Australia-New Zealand and Canadian businesses.

Between 2008 and 2009 Peter was the president and CEO of Medingo

Youqneam, an Israel-based technical team that was developing a novel,

low-cost, patient benefit-rich insulin pump for Type I and II diabetic

patients. He optimized the business, resulting in its ultimate sale to

Roche. Previously, Peter held leadership positions at Medtronic in their

Spinal and Biologics business where he oversaw revenue growth from

approximately $500 million to $2.8 billion in five years. He started his

career with DePuy, a Johnson & Johnson company.

MKT-00612 Rev. A